Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07628049 · ClinicalTrials.gov registry record · Phase 1
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 1,808
- Enrollment target
NCT07628049 is a Phase 1 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,808 participants.
The verdict
NCT07628049, a Phase 1 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,808 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
Interventions
- BIOLOGICAL RSV/hMPV_V low dose vaccine
- BIOLOGICAL RSV/hMPV_V medium dose vaccine
- BIOLOGICAL RSV/hMPV_V high dose vaccine
- BIOLOGICAL RSV/hMPV_W low dose vaccine
- BIOLOGICAL RSV/hMPV_W medium dose vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,808 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2029-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07628049
The ClinicalTrials.gov registry entry for NCT07628049 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 1,808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which RSV/hMPV_V low dose vaccine is the first listed.
NCT07628049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07628049 about?
NCT07628049 is a clinical study titled "A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults". The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
What is the current status of trial NCT07628049?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,808 participants. The study started on 2026-06-05. Estimated completion is 2029-04-05.
What interventions are being tested in trial NCT07628049?
The interventions under investigation include: RSV/hMPV_V low dose vaccine (BIOLOGICAL), RSV/hMPV_V medium dose vaccine (BIOLOGICAL), RSV/hMPV_V high dose vaccine (BIOLOGICAL), RSV/hMPV_W low dose vaccine (BIOLOGICAL), RSV/hMPV_W medium dose vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07628049?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.